MedTrace Logo

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

NCT06494878 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8805

Last updated 2026-07-27

No results posted yet for this study

Summary

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Conditions

Interventions

DRUG

Aspirin

75-100 mg taken once daily by mouth.

DRUG

Low-molecular-weight heparin

Low-molecular-weight heparin injections daily as prescribed by the treating physician.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • European Clinical Research Infrastructure Network

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Leslie Skeith, MD · University of Calgary

  • Marc Rodger, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-04
Primary Completion
2030-09-30
Completion
2030-12-31

Countries

  • Belgium
  • Canada
  • Denmark
  • France
  • Ireland
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06494878 on ClinicalTrials.gov